what are the long-term effects of glp-1 long term glp 1 use Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients GLP-1 medications are changing obesity

The present review ultimately weighs early concerns against increasingly consistent evidence that GLP-1 RA use does not raise overall cancer risk, clarifies that breast cancer risk appears neutral, and further highlights key mechanisms, such as the reduction of hyperinsulinemia and immune-microenvironment modulation, through which these drugs may improve rather than exacerbate malignancy outcomes

Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue

I learned so much on all the ways to research effectively, thoroughly and truthfully

doi: 10.3390/nu15224809

Steven Heymsfield finds that a GLP-1 therapy combined with bimagrumab, an investigational agent that blocks activin signaling pathways, results in greater weight reduction than either drug alone A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue

Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity, again the same drug under different names